SS-31 Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about SS-31 dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for SS-31.
Dosing Protocols
Foundation protocol for SS-31 is designed for users who want to cautiously explore whether mitochondrial-targeted peptide therapy produces subjective or measurable benefits before committing to higher-intensity protocols. This protocol is appropriate for users who have already optimized foundational mitochondrial support (exercise, sleep, nutrition, basic supplements like CoQ10 and NMN) and want to add SS-31 as an experimental refinement.
Pre-start preparation: Before starting SS-31, verify you have no absolute contraindications (pregnancy/lactation, active severe cardiac disease without cardiology oversight, active cancer without oncology approval, known peptide allergy). Ideally establish baseline measurements including inflammatory markers (hs-CRP), metabolic panel, CBC, liver function tests, and any domain-specific markers relevant to your goals (ejection fraction if cardiac focus, muscle function testing if sarcopenia focus, cognitive testing if neurologic focus). Obtain pharmaceutical-grade elamipretide through a reputable specialty compounding pharmacy if possible, or if using research peptide products, select suppliers that provide third-party certificates of analysis.
Reconstitution preparation: SS-31 is typically supplied as lyophilized powder in 10-20 mg vials. Reconstitute with bacteriostatic water (0.9% benzyl alcohol preservative) at a ratio that produces a convenient injection volume — for example, adding 2 mL of bac water to a 20 mg vial produces 10 mg/mL concentration, so a 5 mg dose requires 0.5 mL. Inject bac water slowly down the vial wall to minimize foaming; swirl gently to dissolve; do not shake vigorously. Verify visual clarity of the reconstituted solution (should be clear, colorless, particle-free). Store reconstituted solution in refrigerator; use within 28-30 days or per manufacturer labeling.
Weeks 1-2 (gradual introduction): Start at 5 mg subcutaneous daily for 7 days, increasing to 10 mg daily for the second week if well-tolerated. This gradual introduction allows assessment of individual tolerance without committing to higher doses. Subcutaneous injection technique: use insulin syringes (30g x 5/16 inch typically appropriate); inject into abdominal subcutaneous tissue, thigh, or upper arm; rotate injection sites to prevent local reactions; inject slowly to minimize discomfort. Track any symptoms daily in simple log — injection site reactions, energy levels, sleep quality, any new symptoms.
Weeks 3-4 (standard dose establishment): If well-tolerated through weeks 1-2, increase to 20-40 mg daily subcutaneous. Most clinical trial protocols use 40 mg daily for elamipretide; users may stay at 20 mg daily for cost-conscious protocols with expectation of more modest effects. Continue daily symptom tracking. Add quantitative measures where feasible (HRV monitoring, fitness metrics, subjective well-being scales).
Weeks 5-12 (steady state assessment): Continue at established dose. Reassess baseline measurements at weeks 8-12 (inflammatory markers, metabolic panel, CBC). Compare to pre-start baseline. Assess subjective response against expectations. Most users will not see dramatic transformation; look for subtle improvements in target domains (energy, exercise recovery, cognitive clarity, cardiac symptoms if applicable).
Month 3-6 (continuation or discontinuation decision): Based on tolerability and perceived benefit, decide whether to continue long-term, reduce frequency (several times weekly rather than daily), or discontinue. Continuing without clear benefit at month 3-6 is reasonable for users targeting long-term preventive effects but is also the most expensive pattern without confidence in returns. Users without clear benefit may reasonably discontinue and invest resources in other interventions.
Foundation protocol dose: 5-10 mg subcutaneous daily for first 1-2 weeks, then 20-40 mg daily for 12 weeks minimum assessment period. Subcutaneous injection into abdominal fat, thigh, or upper arm, rotating sites. Morning administration preferred for most users. Use bacteriostatic water for reconstitution; store refrigerated; discard after 28-30 days. This protocol provides a conservative introduction to SS-31 with structured assessment, appropriate for users prioritizing safety and cost management.
Intermediate protocol for users who have completed a successful foundation trial, tolerated SS-31 well, observed evidence of benefit (subjective or biomarker), and want to pursue sustained intermediate-intensity use. This protocol uses the standard clinical trial dose and frequency and represents the mainstream intermediate approach.
Standard dosing: 40 mg subcutaneous daily, consistent with MMPOWER-3, TAZPOWER, and other major clinical trials. Daily dosing rather than intermittent administration is preferred for chronic mitochondrial support, reflecting the pharmacokinetic profile (tissue half-life allows daily maintenance) and clinical trial dosing convention. Some users shift to 5-6 days weekly (skip weekend or 1-2 other days) as a cost-management approach with minimal expected impact on effect; evidence for this is limited but the practice is widespread.
Injection technique and site rotation: Continue using insulin syringes with appropriate gauge (typically 30g x 5/16 inch). Maintain strict injection site rotation across multiple sites: left abdomen, right abdomen, left thigh, right thigh, left upper arm, right upper arm. Rotating through 6-8 sites in sequence allows each site to recover for a week or more between injections, minimizing accumulated local reactions. Monitor for persistent induration, erythema, or skin changes that may require site-specific discontinuation.
Timing and administration: Morning administration (after breakfast) is preferred for most users, aligning with natural circadian mitochondrial rhythms and avoiding interference with sleep. Users preferring evening administration report no consistent differences. Consistency in timing (within 2-3 hours each day) supports stable biological rhythms and makes it easier to detect patterns in response.
Monitoring and adjustment: Monthly tracking of subjective markers and quarterly laboratory monitoring (metabolic panel, CBC, inflammatory markers, organ function). Continue tracking any domain-specific markers relevant to individual goals. Review and adjust protocol every 3-6 months based on tolerance and observed effects. For users with specific clinical conditions (cardiac, neurologic, metabolic), work with appropriate specialist physicians who can integrate SS-31 with broader clinical management.
Stacking coordination: At the intermediate level, SS-31 is typically used alongside a fully built mitochondrial stack: daily NMN 500-1000 mg, ubiquinol 100-300 mg, creatine 5 g, omega-3 2-3 g EPA/DHA, urolithin A 500-1000 mg, possibly weekly rapamycin under physician supervision. The cumulative cost of such a stack is significant; users committing to intermediate-level mitochondrial optimization typically budget hundreds to thousands of dollars monthly for supplements and peptides combined.
Cycling considerations: Some users cycle SS-31 (for example, 8 weeks on, 4 weeks off) rather than continuous use, reasoning that periodic breaks may prevent adaptive responses that could reduce efficacy. The evidence for SS-31 cycling is limited; published clinical trials typically used continuous dosing for treatment periods of weeks to months. Cycling can be considered for cost management or subjective preference but is not required for tolerability or safety.
Addressing tolerance questions: If a user initially responded to SS-31 but perceives diminishing effect over months, options include taking a 2-4 week break (to re-establish responsiveness), increasing dose modestly (not recommended without physician oversight), adding complementary interventions (urolithin A, MOTS-c), or reconsidering whether the original response was placebo. Tolerance to SS-31 as a pharmacologic phenomenon has not been well-characterized.
Cost considerations at intermediate intensity: Pharmaceutical-grade elamipretide costs thousands of dollars per month at standard clinical trial doses. Research peptide SS-31 from specialty suppliers may cost $100-500 monthly depending on quality tier and supplier. Users should honestly evaluate whether continued intermediate-intensity use is affordable and appropriate given personal financial context, and should not extend cost commitments beyond comfortable range.
Intermediate protocol dose: 40 mg subcutaneous daily (or 5-6x weekly with 1-2 rest days for cost management), continuous use with periodic reassessment every 3-6 months. Strict injection site rotation across multiple sites. Morning administration preferred. Integrated with comprehensive mitochondrial stack. Regular quarterly laboratory monitoring and specialist physician oversight for users with clinical conditions. This intermediate protocol represents the mainstream long-term approach for users committed to sustained SS-31 use.
Advanced protocol for users with extensive experience on SS-31, specific clinical indications requiring higher-intensity intervention, or willingness to assume additional risk for potentially greater benefit. This protocol is appropriate only for highly engaged users working with specialist physicians and should not be pursued casually.
Higher dose ranges: Some advanced protocols use 60-80 mg subcutaneous daily, above the 40 mg clinical trial standard. The evidence for higher doses is limited — most pivotal trials used 40 mg, and dose-response relationships in humans are not well-characterized. Theoretical rationale for higher doses includes better tissue exposure in treatment-resistant cases, saturation of cardiolipin stabilization effects, or cases where standard dosing produced biomarker but not clinical response. Risks include greater tolerability concerns, cost, and unknown long-term effects at super-standard doses.
Twice-daily dosing: Split dosing (20 mg twice daily, or 40 mg twice daily for higher total doses) may improve steady-state plasma levels and tissue exposure. Evidence is limited; the short plasma half-life (2-4 hours) supports the theoretical rationale for divided dosing, but tissue half-life (longer due to cardiolipin binding) argues that once-daily dosing is pharmacodynamically adequate. Advanced users may try twice-daily as a variant but should monitor tolerability carefully.
Combined peptide protocols: Advanced mitochondrial peptide stacks may combine SS-31 with MOTS-c (typical dose 5-10 mg subcutaneous 2-3x weekly), humanin (typical dose 5-10 mg subcutaneous 2-3x weekly or daily), and less commonly other investigational mitochondrial peptides. These combinations are experimental and costly; evidence for additive or synergistic benefit beyond SS-31 alone is limited. Users pursuing combined protocols should layer one peptide at a time, establish tolerability of each individually before combining, and maintain comprehensive monitoring.
Specific clinical indications: Users with primary mitochondrial myopathies, Barth syndrome, severe cardiomyopathy, chronic kidney disease with mitochondrial component, or other specific mitochondrial-relevant conditions may pursue higher-intensity SS-31 regimens under specialist (cardiology, nephrology, neurology, or mitochondrial disease) physician oversight. These physician-supervised clinical regimens for specific indications are distinct from experimental longevity use and should be directed by the clinician familiar with the individual case.
Biomarker-driven titration: Advanced users may use biomarker panels (inflammatory markers, mitochondrial-specific biomarkers, domain-relevant measures) to titrate dose and frequency. This approach requires access to appropriate testing and interpretation. Candidate biomarkers include high-sensitivity cardiac troponin (for cardiac applications), NT-proBNP (heart failure), exercise capacity metrics (VO2max, 6-minute walk), cognitive assessments, and specialized mitochondrial assays where available.
Combined with pharmaceutical interventions: In specific clinical contexts, SS-31 may be combined with conventional disease-specific pharmaceuticals — heart failure medications, cognitive enhancers, immunomodulators — under specialist physician care. These integrated protocols address both disease-specific pathology and mitochondrial support.
Long-term trajectory planning: Advanced users should actively consider their 5-10 year trajectory. Will SS-31 use continue indefinitely? At what point does continued use become imprudent given cumulative cost without clear clinical validation? How will emerging mitochondrial therapies (new cardiolipin stabilizers, novel mitochondrial-targeted compounds, cellular therapies) change the decision landscape? These strategic questions benefit from physician partnership and honest self-assessment.
Research participation: Users with specific conditions that match SS-31 clinical trials may consider participation in ongoing clinical research rather than off-label use. Clinical trial participation provides access to pharmaceutical-grade compound, comprehensive monitoring, appropriate informed consent, and contribution to the evidence base. Check ClinicalTrials.gov for active SS-31/elamipretide studies and discuss eligibility with your physician.
Ethical considerations: Advanced SS-31 use represents a substantial commitment of resources and assumption of risk in exchange for uncertain benefit. Users should maintain clarity about the limitations of the evidence, avoid commercial overclaiming influence, and be willing to update strategy based on evolving data. The advanced protocol is an evolving best-approximation, not a validated long-term strategy.
Advanced protocol ranges: 40-80 mg subcutaneous daily or twice-daily, potentially combined with complementary mitochondrial peptides (MOTS-c, humanin), biomarker-driven titration, physician-supervised integration with disease-specific treatment, continuous reassessment and updating based on emerging evidence. Appropriate only for users with specific clinical indications or high commitment to experimental mitochondrial optimization under specialist oversight.
Commonly Stacked With
SS-31's mitochondrial-specific mechanism makes it a natural complement to other mitochondrial interventions rather than a substitute. A well-designed mitochondrial longevity stack addresses multiple aspects of mitochondrial biology — cardiolipin/membrane integrity (SS-31), NAD+ supply (NMN/NR), electron transport chain cofactors (CoQ10), substrate availability (creatine, carnitine), quality control (urolithin A, rapamycin), and signaling (mitochondrial-derived peptides, AMPK activators). SS-31 fits into this stack as a specific tool for inner membrane stabilization without duplicating other interventions.
NMN / NR (NAD+ precursors): NMN and nicotinamide riboside elevate cellular NAD+, supporting sirtuin activity, PARP-mediated DNA repair, Complex I substrate availability, and general mitochondrial function. The mechanism is complementary to SS-31: NAD+ supply supports the biochemical capacity of the electron transport chain, while SS-31 preserves the structural integrity that allows efficient use of that capacity. Both are considered foundational to comprehensive mitochondrial stacks. No adverse interactions have been reported; the combination is standard in longevity protocols. Typical stacking: daily NMN 250-1000 mg + SS-31 40 mg subcutaneous daily or several times weekly.
CoQ10 and ubiquinol: CoQ10 is an essential electron transport chain cofactor and mitochondrial antioxidant. In conditions of CoQ10 deficiency (statin use, aging, primary CoQ10 deficiency, mitochondrial disease), CoQ10 supplementation supports electron transport function. SS-31 complements CoQ10 by stabilizing the membrane environment where CoQ10 operates; the combination may be particularly valuable in users with known mitochondrial dysfunction. Typical stacking: 100-300 mg CoQ10 (as ubiquinol for better absorption) daily + SS-31.
Urolithin A: Urolithin A induces mitophagy, the selective clearance of damaged mitochondria. Combined with SS-31's stabilization of healthy mitochondria, this provides a balanced approach: preserve the good, clear the bad. Preclinical data suggest these mechanisms are complementary and potentially synergistic. Typical stacking: 500-1000 mg urolithin A daily + SS-31.
MOTS-c and humanin: MOTS-c and humanin are mitochondrial-derived peptides with systemic effects on insulin sensitivity, metabolic health, and neuronal protection. The mechanisms differ from SS-31 (MOTS-c and humanin are signaling molecules with receptor-mediated effects; SS-31 is a structural stabilizer). The combination addresses mitochondrial biology from both structural and signaling angles. Users pursuing comprehensive mitochondrial peptide stacks may combine SS-31 with MOTS-c and humanin, though costs accumulate rapidly and evidence for additive benefit is limited.
Creatine and phosphocreatine: Creatine supports cellular energetics through the phosphocreatine-creatine kinase system, buffering ATP in high-energy-demand tissues (muscle, brain). The mechanism is complementary to SS-31 — creatine supports energy buffering, SS-31 preserves mitochondrial ATP production capacity. The combination is safe and broadly used. Typical stacking: 3-5 g creatine monohydrate daily + SS-31.
Omega-3 fatty acids (EPA/DHA): EPA and DHA are incorporated into mitochondrial membrane phospholipids, influencing membrane fluidity, protein-lipid interactions, and inflammatory signaling. The mechanism differs from SS-31's cardiolipin-specific effects but addresses overlapping membrane biology. Safe to stack; likely complementary at the membrane level.
Rapamycin: Rapamycin inhibits mTORC1, promoting autophagy and mitophagy and addressing the growth-aging tradeoff. Weekly pulsed rapamycin dosing integrates naturally with daily SS-31 support. The combination addresses different mitochondrial aspects (quality control via rapamycin, structural stability via SS-31) and is used in comprehensive longevity stacks under physician supervision.
Fisetin and other senolytics: Fisetin clears senescent cells; SS-31 supports healthy mitochondrial function. The mechanisms are complementary, with senolytic clearance removing dysfunctional cells and SS-31 preserving mitochondrial function in remaining healthy cells. Periodic fisetin pulses combined with daily SS-31 is a reasonable pattern.
Antioxidants (NAC, glutathione, vitamin E, vitamin C): Conventional antioxidants like NAC, glutathione, vitamin E, and vitamin C scavenge ROS after production. SS-31 reduces ROS production at its source. The mechanisms are complementary rather than redundant: addressing both ROS generation and ROS neutralization provides more complete coverage than either alone. Safe to stack; commonly combined in comprehensive protocols.
Exercise: Regular aerobic and resistance exercise is the most potent mitochondrial biogenesis stimulus available, upregulating PGC-1α, increasing mitochondrial content, improving respiratory capacity, and enhancing mitophagy. SS-31 does not replace exercise but complements it; exercise generates new, healthy mitochondria while SS-31 preserves the function of existing mitochondria. Users committed to mitochondrial health should prioritize exercise as foundational and add SS-31 as refinement.
Caloric restriction and time-restricted eating: Caloric restriction and time-restricted eating induce mitochondrial biogenesis, mitophagy, and improved mitochondrial function through mechanisms including AMPK activation, mTOR suppression, and sirtuin activation. Compatible with SS-31; likely complementary effects on mitochondrial health.
Curcumin and other polyphenols: Curcumin, resveratrol, and other polyphenols modestly improve mitochondrial function through various mechanisms (PGC-1α induction, Nrf2 activation, anti-inflammatory signaling). Safe to stack with SS-31; adds supportive coverage without mechanism overlap.
What not to stack: Avoid combining SS-31 with unvalidated research peptides of unclear quality, which adds cumulative risk without proportional benefit. Avoid using SS-31 as a substitute for treating identified medical conditions that have evidence-based therapies. Avoid extreme combination stacking where multiple peptides and compounds are added simultaneously without establishing tolerability of each individually.
Foundation stack for mitochondrial optimization: A rational foundation stack for users seriously pursuing mitochondrial health might include daily NMN 500 mg + CoQ10 (ubiquinol) 200 mg + creatine 5 g + omega-3 (EPA/DHA) 2 g + urolithin A 500 mg + exercise (aerobic 3-5x/week, resistance 2-3x/week) + adequate sleep and nutrition. SS-31 40 mg subcutaneous daily or several times weekly can be added to this foundation for users desiring more intensive intervention, with the understanding that incremental benefit from SS-31 may be modest given saturation of mitochondrial support from the foundation.
Side Effects & Safety
Contraindications
Contraindications for SS-31 (elamipretide) reflect a combination of specific safety concerns documented in clinical trials, theoretical risks based on mechanism and pharmacology, and general caution appropriate for investigational peptide therapy. Because SS-31 remains investigational for most uses and consumer adoption operates outside regulatory approval pathways, users should approach contraindications conservatively. Pregnancy: SS-31 should not be used during pregnancy. No adequate safety studies in pregnant women exist, and the theoretical concerns about peptide exposure during fetal mitochondrial development argue for avoidance. Women of reproductive potential using SS-31 should use reliable contraception and discontinue SS-31 if pregnancy occurs or is planned. Women with Barth syndrome or other specific mitochondrial diseases of reproductive age should consult mitochondrial specialists and reproductive medicine physicians before making decisions about continued use. Lactation: SS-31 should not be used during breastfeeding. Whether elamipretide or its metabolites are excreted into breast milk is unclear; given the theoretical potential for effects on infant mitochondrial development and the absence of pediatric safety data in this context, avoidance is appropriate. Women completing SS-31 regimens before pregnancy should allow adequate washout time before conception; evidence-based washout guidance is not established but several half-lives of the compound (tissue half-life in weeks) would be conservative. Active severe cardiac disease without cardiology oversight: While SS-31 has been studied in cardiac disease (heart failure, hypertrophic cardiomyopathy), its effects in severe cardiac disease can be complex. Users with severe heart failure, unstable cardiac disease, recent myocardial infarction, or significant cardiac arrhythmia should not start SS-31 without cardiology consultation and oversight. The investigational status of SS-31 in cardiac applications means that informed medical oversight is essential for users with meaningful cardiac disease. Known peptide allergy: Users with documented severe allergic reactions to peptide medications (certain GLP-1 agonists, insulin, other peptide therapeutics) should not use SS-31 without allergy specialist consultation. Cross-reactivity with specific peptides is variable, but peptide allergy history increases risk of reaction to new peptide introductions. Active cancer without oncology approval: Cancer cells often have altered mitochondrial biology, and SS-31's effects on mitochondrial function could interact with cancer biology in unpredictable ways. Users with active cancer should not use SS-31 without discussion with their oncologist. Cancer in remission may allow SS-31 use but still warrants oncology discussion before starting. Active severe infection or sepsis: Systemic infection alters mitochondrial function dramatically; SS-31's effects during sepsis or severe systemic infection have not been well-characterized. Users with active severe infection should not initiate SS-31 and should pause ongoing use during severe illness until recovery. Active autoimmune disease on aggressive immunomodulation: Users on high-dose immunosuppressants, biologic agents for autoimmune disease, or active immunotherapy should discuss SS-31 with their rheumatologist or immunologist before use. Interactions are theoretical but warrant specialist input. Pediatric use: Outside specific clinical trial contexts and Barth syndrome approval in adolescent age ranges, pediatric use of SS-31 for longevity or off-label indications is not appropriate. No established safety or efficacy data for general pediatric use exists. Research peptide product concerns: Users obtaining SS-31 from research chemical suppliers or unverified sources assume additional risks related to product quality, purity, contamination, and identity. Severe reactions to contaminated or mislabeled products are possible and would not reflect intrinsic SS-31 safety. Users should seek the highest quality sources accessible (pharmaceutical-grade elamipretide through specialty pharmacies where feasible; reputable research suppliers with third-party certificates of analysis as second choice) and exercise caution with unverified products. Severe hepatic impairment: SS-31 pharmacokinetics in severe liver disease have not been well-characterized. Aminopeptidase metabolism and renal excretion dominate SS-31 clearance, but users with severe hepatic impairment (Child-Pugh C cirrhosis) should exercise caution and consult hepatology. Severe renal impairment: Renal excretion is the primary route for SS-31 metabolites. Users with severe renal impairment (eGFR less than 30 mL/min/1.73 m²) or dialysis-dependent kidney disease should consult nephrology before starting SS-31. Dose adjustment may be appropriate. Active central nervous system disease: Users with active neurodegenerative disease in acute phases, recent stroke, severe seizure disorders, or active CNS infections should exercise particular caution and coordinate with neurology. Perioperative period: SS-31 should generally be paused for major elective surgery unless specifically indicated for perioperative use (for example, cardiac surgery in Barth syndrome patients under specialist direction). Resume SS-31 after recovery. Concurrent investigational therapies: Users participating in clinical trials should disclose all supplements and off-label therapies to trial investigators; most clinical trials prohibit concurrent investigational therapies that could confound results or safety monitoring. Specific drug interactions to consider: Theoretical interactions with drugs affecting mitochondrial function (metformin, statins, valproate, some antiretrovirals like NRTIs) have not been systematically studied. Most interactions appear clinically modest. Users on these drugs should review with physician but do not necessarily need to avoid SS-31. Age extremes: No specific evidence argues against use in healthy older adults (ages 60-90) who are otherwise appropriate candidates. Very elderly users (90+) have limited data and should individualize based on overall health status. Younger adults (under 30) without specific clinical indications have less rationale for SS-31 use and should consider whether the experimental nature of the intervention matches their goals. Quality-of-life versus extension considerations: For patients near end of life from terminal disease, the cost-benefit calculus for SS-31 use shifts; some specialist physicians may integrate SS-31 into palliative mitochondrial support protocols, but this is an advanced clinical decision rather than general consumer use. When to discuss SS-31 with a physician before starting: All users with chronic medical conditions, users on multiple prescription medications, users with cancer history, users with active clinical research participation, users with complex cardiovascular, neurologic, or metabolic disease, users approaching major medical procedures. For most otherwise-healthy adults pursuing SS-31 for general mitochondrial optimization, specific medical clearance may not be required, but physician awareness of supplementation is good practice during periodic health visits. Final framing: SS-31 is an investigational peptide therapeutic with regulatory approval in one rare disease (Barth syndrome) and investigational status in all other uses. Off-label consumer use involves assumption of unknown risks in exchange for uncertain benefits. Users should approach with appropriate respect for the limitations of current evidence, exercise conservatism in the face of uncertainty, and maintain honesty about the experimental nature of the intervention.
Additional Notes
SS-31 (elamipretide) is administered by subcutaneous injection, typically once daily, at doses ranging from 20-60 mg in common use. The standard clinical trial dose is 40 mg daily, which serves as the reference dose for most longevity and off-label applications. Dose calculation, timing, and administration technique all influence the practical experience of SS-31 use.
Standard dose: 40 mg subcutaneous daily. This dose has been used in MMPOWER-3, TAZPOWER, ReCLAIM-2, PROGRESS, and other pivotal clinical trials, representing the mainstream reference for human elamipretide dosing. Most users start at or work up to 40 mg daily.
Conservative starting dose: 5-10 mg subcutaneous daily for the first 1-2 weeks, titrating up to 20-40 mg daily over 2-4 weeks. Gradual titration allows tolerability assessment and can reduce initial injection site reactions or systemic effects that may occur with full-dose initiation.
Intermediate maintenance: 20-40 mg subcutaneous daily, selected based on cost constraints, tolerability, and individual goals. 20 mg daily is a common cost-conscious maintenance dose; 40 mg daily aligns with clinical trial standard.
Advanced/higher dose: 60-80 mg subcutaneous daily for users with specific clinical indications under physician supervision. Evidence for higher doses is limited; most should not pursue this without clear rationale.
Frequency variations: Daily dosing is most common and aligns with clinical trial protocols. Some users use 5-6 days weekly (with 1-2 rest days) as a cost-management approach; evidence for equivalence with daily dosing is limited but the practice is widespread. Every-other-day dosing has been used in some smaller studies; it produces lower steady-state exposure but may be considered for maintenance phases. Three-times-weekly dosing is less common and produces significantly lower cumulative exposure.
Timing of daily dose: Morning administration after breakfast is preferred by most users, aligning with circadian mitochondrial activity patterns and avoiding potential sleep interference. Evening administration is acceptable; afternoon is a reasonable compromise. Maintain timing consistency within 2-3 hours each day for stable rhythm.
Weight-based dosing considerations: Clinical trial doses are typically fixed-dose (40 mg) rather than weight-adjusted. Some users with very high or very low body weight consider adjusting proportionally — for example, 30 mg daily for a smaller adult (50-60 kg) or 50-60 mg daily for a larger adult (100+ kg). Evidence for weight-based adjustment is limited; most users use the fixed 40 mg dose regardless of body weight.
Injection site selection: Subcutaneous injection sites include abdomen (preferred due to larger subcutaneous tissue reservoir), anterior or lateral thigh, and upper arm (less accessible for self-injection). Avoid areas with scars, moles, stretch marks, or inflammation. Rotate through at least 4-6 sites in sequence to allow tissue recovery between injections.
Injection technique: Use insulin-type syringes (typically 30g x 5/16 inch or 31g x 5/16 inch for thin skin; 29g x 1/2 inch for abdominal fat in users with more subcutaneous tissue). Clean the injection site with alcohol wipe. Pinch up a skin fold. Insert needle at 45-90 degree angle depending on subcutaneous tissue depth. Inject slowly over 10-30 seconds to minimize discomfort. Withdraw needle. Apply brief pressure to site. Dispose of needle in sharps container.
Measuring doses from reconstituted vials: If a vial contains 20 mg elamipretide reconstituted with 2 mL bac water, concentration is 10 mg/mL. A 40 mg dose therefore requires 4 mL — which is too large a volume for a single subcutaneous injection. Split into two 2 mL injections at different sites, or reconstitute with less bac water (1 mL instead of 2 mL) to produce 20 mg/mL concentration and allow 2 mL single injections. Many users prefer higher concentration (for smaller volumes) but dissolution may be slower and injection site concentration higher.
Common dose measurements with insulin syringes: Insulin syringes are typically marked in units (100 units = 1 mL) or in mL. For a 20 mg/mL reconstituted solution: 40 mg = 2 mL = 200 units; 20 mg = 1 mL = 100 units; 10 mg = 0.5 mL = 50 units. For a 10 mg/mL solution: 40 mg = 4 mL = 400 units (split into two syringes); 20 mg = 2 mL = 200 units; 10 mg = 1 mL = 100 units. Always verify the measurement against the reconstitution concentration used.
Adjusting for cost: Users with budget constraints may reasonably dose at the lower end of the range (20 mg daily rather than 40 mg daily) or with reduced frequency (5x weekly rather than daily) as cost-management strategies. The evidence base does not conclusively establish that higher doses produce proportionally greater benefits; the incremental benefit of 40 mg versus 20 mg is uncertain.
Missed doses: A missed dose can be taken later the same day if noticed, or skipped entirely if the next scheduled dose is within a few hours. Do not double-dose to make up for missed injections. Occasional missed doses have minimal impact on overall protocol goals.
Maximum single-injection volume: Subcutaneous injections are typically limited to 1-2 mL per site to minimize local tissue distension and discomfort. For 40 mg doses with 10 mg/mL concentration (requiring 4 mL), split into two injections at different sites. Higher concentrations (20 mg/mL, 40 mg/mL) allow smaller volumes per injection.
Storage during protocol: Keep reconstituted vials refrigerated (2-8°C; typical home refrigerator). Use within 28-30 days of reconstitution, or per manufacturer labeling. Unreconstituted lyophilized powder has longer shelf life and can be stored refrigerated or frozen per supplier recommendations. Bring vial to room temperature before injection (5-10 minutes out of refrigerator) to reduce injection discomfort from cold solution.
Where to Buy SS-31
Compare 3 listings across 1 vendor — from $45.00
Frequently Asked Questions
What is the recommended SS-31 dosage?
Dosage for SS-31 varies by protocol. Consult a qualified healthcare provider.
How often should I take SS-31?
Administration frequency depends on the specific protocol. Consult current research literature.
Does SS-31 need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are SS-31 side effects?
SS-31 (elamipretide) has been generally well-tolerated across clinical trials spanning over a decade of human exposure, with adverse event profiles dominated by injection site reactions rather than systemic toxicity. This favorable safety profile reflects both the targeted mechanism (mitochondrial membrane stabilization rather than enzyme inhibition or receptor blockade) and the lack of significant off-target interactions with non-mitochondrial machinery. However, the compound remains investigational for most uses, long-term safety data at consumer-use scale are limited, and research-grade peptide products obtained through unregulated suppliers carry additional quality and contamination risks beyond the intrinsic drug profile. Injection site reactions: The most common adverse effects reported with subcutaneous elamipretide are local injection site reactions — redness, swelling, itching, transient pain, and occasional bruising at the injection site. These effects are typically mild and self-limited, resolving within hours to days of the injection. Rotating injection sites (abdomen, thigh, upper arm), using proper injection technique with fresh sterile needles, and ensuring the injected volume is at appropriate temperature (room temperature rather than cold refrigerator temperature) minimizes these reactions. Severe local reactions — significant swelling, persistent pain, induration, abscess, or ulceration — are uncommon but warrant evaluation and discontinuation. Gastrointestinal effects: Mild to moderate gastrointestinal effects — nausea, abdominal discomfort, diarrhea, constipation — have been reported but are less common than injection site reactions. These effects may be mediated through systemic absorption and peripheral cholinergic-like effects, though the specific mechanism is not fully characterized. GI effects typically resolve with continued dosing or with dose reduction. Headache and dizziness: Some users report mild headache or dizziness particularly in early dosing days, typically resolving over 1-2 weeks. The mechanism may relate to transient vascular effects or systemic responses to altered mitochondrial signaling. Persistent or severe headache warrants evaluation for other causes. Fatigue paradox: A small subset of users report increased fatigue initially with SS-31, which may seem counterintuitive given the mitochondrial support rationale. Possible mechanisms include mitochondrial biogenesis adaptation phases, temporary shifts in energy partitioning, or placebo-adjacent individual responses. This effect typically resolves over 1-3 weeks of continued use; persistent fatigue without improvement warrants reassessment. Cardiac effects: Most SS-31 cardiac data in clinical trials involve patients with pre-existing cardiomyopathy or mitochondrial disease, so attributing effects to the compound in otherwise-healthy users is challenging. In clinical trials, cardiac adverse events have generally been balanced between elamipretide and placebo groups. Rare cases of arrhythmia, chest pain, or blood pressure changes have been reported but without clear causal attribution. Users with pre-existing cardiac disease should work with their cardiologist when considering elamipretide. Dermatologic effects: Beyond injection site reactions, systemic rash or allergic skin reactions have been reported rarely. Users with known hypersensitivity to peptide therapies or injectable medications should proceed cautiously. Neurologic effects: Mild paresthesias, transient cognitive effects, or subtle neurologic sensations have been reported rarely. The pattern does not resemble classical neurotoxicity, and most reports are self-limited. Laboratory abnormalities: No consistent laboratory abnormalities have emerged from SS-31 trials. Hematologic parameters, liver enzymes, kidney function, and electrolyte panels have remained stable in most patients. Users on long-term protocols may benefit from periodic monitoring of CBC, comprehensive metabolic panel, and liver function tests as a general safety measure, though specific SS-31-related abnormalities have not been defined. Allergic and hypersensitivity reactions: Like any injectable peptide therapeutic, SS-31 carries theoretical risk of hypersensitivity or allergic reactions. Severe reactions — anaphylaxis, angioedema, severe rash — have not been commonly reported in clinical trials but cannot be excluded in consumer use, particularly with research peptide products of uncertain purity. Users should have basic knowledge of allergic reaction management (oral antihistamines, recognition of anaphylaxis symptoms, when to seek emergency care) before starting any injectable peptide. Research peptide quality concerns: When SS-31 is obtained from research chemical suppliers rather than pharmaceutical-grade sources (Stealth BioTherapeutics' elamipretide), quality becomes a significant safety concern. Research peptides may have impurities, degradation products, endotoxin contamination, or mislabeling (product not matching stated sequence or concentration). Some suppliers provide certificates of analysis from independent third-party labs, which partially addresses quality concerns but does not guarantee pharmaceutical-grade standards. Users obtaining SS-31 from non-pharmaceutical sources assume risks related to product quality that are additional to the intrinsic drug profile. Pregnancy and lactation: SS-31 should not be used during pregnancy or lactation. No safety data exist for these populations, and the theoretical concerns about fetal mitochondrial exposure during development argue for avoidance unless specifically indicated (Barth syndrome patients of reproductive age should consult mitochondrial specialists). Pediatric use: Outside the Barth syndrome approval (which extended into adolescent age ranges in trial populations), pediatric use of SS-31 is not established and is not recommended for off-label consumer use. Active cancer: Patients with active cancer have limited SS-31 safety data. The compound's mitochondrial effects could theoretically interact with cancer biology in complex ways (many cancer cells rely on altered mitochondrial function), and users with active malignancy should discuss SS-31 with their oncologist before starting. Interactions with other medications: No major pharmacokinetic interactions have been identified for SS-31 given its distinctive mechanism and minimal effects on drug-metabolizing enzymes. Theoretical interactions with drugs affecting mitochondrial function (metformin, statins, certain antiretrovirals, valproate) have not been systematically studied but appear clinically modest. Users on complex medication regimens should discuss SS-31 with their pharmacist or physician. Long-term safety unknowns: Because broad consumer use of SS-31 is relatively recent and human exposure beyond clinical trial durations is limited, long-term safety over years to decades is not well characterized. Theoretical concerns include adaptive changes in mitochondrial biology with chronic exogenous cardiolipin stabilization, altered mitochondrial selection dynamics (heteroplasmy shifts in users with mtDNA variants), and effects on mitochondrial biogenesis signaling over extended exposure. Users commit to long-term SS-31 use without complete safety assurance, and periodic reassessment (every 6-12 months) of continued use is prudent. Drug misuse and identity concerns: Because SS-31 is obtained from various sources including research chemical suppliers, counterfeit products are a real concern. Products labeled as "SS-31" or "elamipretide" may contain different peptides, different concentrations than labeled, or adulterants. Users pursuing SS-31 should source from the most reputable suppliers available, request certificates of analysis, and remain alert to product-specific concerns. When to stop SS-31: Discontinue and seek medical evaluation for any severe reaction, persistent systemic symptoms, signs of infection at injection sites, unexplained new cardiac, neurologic, or allergic symptoms, or failure to observe expected benefits over a reasonable trial period (2-3 months). Most users who discontinue do so because of cost, administrative burden, or insufficient perceived benefit rather than acute adverse events.
Where can I buy SS-31?
Compare 3 listings from 1 vendor on our price comparison page — starting from $45.00.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
